VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Twice amended) A method for identifying a compound that is an agonist of Ret-independent intracellular signaling effected by GPI-anchored receptors in nervous system cells comprising (i) incubating [said] nervous system cells [having] expressing GPI-anchored receptors, but not Ret, with a test compound and (ii) determining whether intracellular signaling has been effected in said cells, thereby identifying a compound that is an agonist of Ret-independent intracellular signaling effected by said GPI-anchored receptors.

16. (Twice amended) A method for identifying a compound that is an antagonist of Ret-independent intracellular signaling effected by GPI-anchored receptors in nervous system cells comprising (i) incubating [said] nervous system cells [having] expressing GPI-anchored receptors, but not Ret, with a test compound in the presence of a sufficient amount of an agonist of said Ret-independent intracellular signaling to effect intracellular signaling, and [(iii)] (ii) comparing the results to controls not incubated with said compound, thereby identifying a compound that is an antagonist of Ret-independent intracellular signaling effected by GPI-anchored receptors.

83. (Twice amended) A method for identifying a compound which is an agonist of Ret-independent intracellular signaling effected by GFRα receptors comprising (i) incubating

lipid rafts prepared from cells having GFRα receptors with said compound and (ii) determining whether Src-type kinase is activated as compared to controls not incubated with said compound, thereby identifying a compound which is an agonist of Ret-independent intracellular signaling effected by GFRα receptors.

87. (Twice amended) A method for identifying a compound which is an antagonist of Ret-independent intracellular signaling effected by GFRα receptors comprising (i) incubating lipid rafts prepared from cells having GFRα receptors with said compound in the presence of a sufficient amount of an agonist of the GFRα-dependent, Ret-independent intracellular signaling pathway to activate Src-type kinases and (ii) comparing the results to control experiments performed in the absence of said compound, thereby identifying a compound which is an antagonist of Ret-independent intracellular signaling effected by GFRα receptors.